Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Receivables (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Receivables for 17 consecutive years, with $285.7 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 2.58% to $285.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $285.7 million through Dec 2025, up 2.58% year-over-year, with the annual reading at $285.7 million for FY2025, 2.58% up from the prior year.
  • Receivables hit $285.7 million in Q4 2025 for Integra Lifesciences Holdings, up from $267.1 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $288.0 million in Q2 2025 to a low of $230.0 million in Q1 2021.
  • Historically, Receivables has averaged $259.5 million across 5 years, with a median of $260.8 million in 2023.
  • Biggest YoY gain for Receivables was 27.46% in 2021; the steepest drop was 9.25% in 2021.
  • Year by year, Receivables stood at $243.2 million in 2021, then increased by 12.47% to $273.6 million in 2022, then fell by 1.84% to $268.6 million in 2023, then grew by 3.71% to $278.5 million in 2024, then increased by 2.58% to $285.7 million in 2025.
  • Business Quant data shows Receivables for IART at $285.7 million in Q4 2025, $267.1 million in Q3 2025, and $288.0 million in Q2 2025.